FDA Finds More Action Required in Less Developed Nations – and Denver
This article was originally published in The Gold Sheet
FDA inspection data shows a clear trend over the past four years: Investigators are somewhat more likely to find GMP issues at manufacturing facilities in less developed nations and less developed regions. However, the data shows more pronounced variation among FDA districts in the U.S., with some finding far greater needs for corrective action than others.
You may also be interested in...
US HHS turns to COVID-19 vaccine distributor to assemble vaccine administration kits, citing revised vaccine delivery schedule.
Stand-alone bill headed for Senate, where it fared poorly in coronavirus response legislative packages.
Agency begins gathering manufacturing plant data to prepare for disruptions that can drain inventories over a weekend.